•  
• Tweet
•  
•  
•        Print
•  
•        Email
•  
•         Track Keywords

Moreover, the Board of Directors has been further fortified with the addition of Christoph Schwarzenbach. Having successfully built and financed four longevity companies, including Avea and Biolytica, Maximon has increased the investment volume of its longevity co-investment fund to CHF 30 million ($33m), with Maximon's own investment rising to CHF 10 million. Notably, new investors such as European family offices and private investors have joined the initiative. The fund's target volume is set at CHF 100 million.

Dr. Tobias Reichmuth, a founding partner at Maximon, expressed his satisfaction, stating, "In the current market environment, fundraising is no easy task. Therefore, we are particularly pleased to have attracted additional investors with significant capital to support our longevity-focused company building." Dr. Dr. Elisabeth Roider, Partner and Chief Medical Officer at Maximon, highlighted the increasing interest in longevity, stating, "Longevity is a subject of growing fascination. The scientific advancements in this field are tremendous. Now, it is crucial to foster entrepreneurship to transform research outcomes into tangible products."

By welcoming Christoph Schwarzenbach, a senior partner at the esteemed family office FINAD, as a new Board of Directors member, the company builder has gained another experienced investor and asset manager. Maximon's objective is to establish two more companies within the current year and nearly a dozen longevity companies over the next four years, providing them with funding of up to CHF 10 million each. This level of seed financing will enable these companies to secure internationally competitive Series A funding in the double-digit million range, paving the way for the creation of globally active longevity companies.